Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
Cancer Res Treat. 2018;50(3):691-700.   Published online 2017 Jul 6     DOI: https://doi.org/10.4143/crt.2017.280
Citations to this article as recorded by Crossref logo
Performance of Japanese patients in registrational studies
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Japanese Journal of Clinical Oncology.2022; 52(1): 53.     CrossRef
Targeted therapy for advanced anaplastic lymphoma kinase (ALK )-rearranged non-small cell lung cancer
Laird B Cameron, Nadia Hitchen, Elias Chandran, Tessa Morris, Renée Manser, Benjamin J Solomon, Vanessa Jordan
Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
Kai Chen, Yingnan Si, Jia-Shiung Guan, Zhuoxin Zhou, Seulhee Kim, Taehyun Kim, Liang Shan, Christopher D. Willey, Lufang Zhou, Xiaoguang Liu
Biomedicines.2022; 10(1): 130.     CrossRef
The application of radiomics in predicting gene mutations in cancer
Yana Qi, Tingting Zhao, Mingyong Han
European Radiology.2022; 32(6): 4014.     CrossRef
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D. Ross Camidge, Karin Berghoff, Soetkin Vlassak, Paul K. Paik
Clinical Lung Cancer.2022; 23(3): 195.     CrossRef
Role of STK11 in ALK‑positive non‑small cell lung cancer (Review)
Wen Zhou, Lu-Da Yan, Zhi-Qiong Yu, Na Li, Yong-Hua Yang, Meng Wang, Yuan-Yuan Chen, Meng-Xia Mao, Xiao-Chun Peng, Jun Cai
Oncology Letters.2022;[Epub]     CrossRef
Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
Mei-ting Chen, Xiao-hong Fu, He Huang, Zhao Wang, Xiao-jie Fang, Yu-Yi Yao, Quan-Guang Ren, Ze-geng Chen, Tong-yu Lin
Leukemia & Lymphoma.2021; 62(3): 571.     CrossRef
Breakthrough in targeted therapy for non-small cell lung cancer
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Biomedicine & Pharmacotherapy.2021; 133: 111079.     CrossRef
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
Daniel S.W. Tan, Sarayut Geater, Chong-Jen Yu, Chun-Ming Tsai, Te-Chun Hsia, Jun Chen, Meng-Chih Lin, You Lu, Virote Sriuranpong, Cheng-Ta Yang, Paramita Sen, Fabrice Branle, Michael Shi, Yi-Long Wu
JTO Clinical and Research Reports.2021; 2(3): 100131.     CrossRef
Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
Wenbin Li, Jing Zhang, Zhijie Wang, Lin Li, Jie Ma, Xiaoyang Zhou, Jie Wang, Zhiyong Liang, Jianming Ying
Journal of the National Cancer Center.2021; 1(4): 123.     CrossRef
Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study
Fenge Jiang, Congcong Wang, Ping Yang, Ping Sun, Jiannan Liu
World Journal of Surgical Oncology.2021;[Epub]     CrossRef
Genetic Analysis of Pediatric Pancreatoblastoma
Zhengzheng Wang, Xiaoting Li, Qingjun Li, Jinxue Zhou
Pancreas.2021; 50(10): 1445.     CrossRef
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi
The Lancet Respiratory Medicine.2020; 8(1): 45.     CrossRef
Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
Lan Song, Zhenchen Zhu, Li Mao, Xiuli Li, Wei Han, Huayang Du, Huanwen Wu, Wei Song, Zhengyu Jin
Frontiers in Oncology.2020;[Epub]     CrossRef
Renal complication of crizotinib: Crizotinib-associated complex renal cyst
Warissara Jutidamrongphan, Pimporn Puttawibul
The ASEAN Journal of Radiology.2020; : 44.     CrossRef
A Unique Case of a High-Grade Neuroepithelial Tumor With EML4-ALK Fusion in a Five-Month-Old
Oliver D Mrowczynski, Russell Payne, Cunfeng Pu, Robert Greiner, Elias Rizk
Cureus.2020;[Epub]     CrossRef
Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement
Daniel S. Grosser, Haiying Zhang
Baylor University Medical Center Proceedings.2019; 32(2): 206.     CrossRef
ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib
Ye Qiu, Bixun Li, Yihong Zhang, Xiaoyun Guo, Chunzhi Xiang, Congshui Wang, Yang Lu, Shuang Ren, Juan Zhao
Medicine.2019; 98(11): e14826.     CrossRef
Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
Journal of Hematology & Oncology.2019;[Epub]     CrossRef
De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
Jing-Wen Li, Shu-Hui Cao, Jian-Lin Xu, Hua Zhong
Cancer Biology & Therapy.2019; 20(9): 1183.     CrossRef
Incidence and risk of fatigue in cancer patients treated with MET inhibitors
Hongxuan Tong, Yutian Zhu, Yihua Liu
Medicine.2019; 98(22): e15522.     CrossRef
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo, Yingliang Wu
RSC Advances.2019; 9(31): 17921.     CrossRef
Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
Shih‐Hao Huang, Allen Chung‐Cheng Huang, Chin‐Chou Wang, Wen‐Chen Chang, Chien‐Ying Liu, Stelios Pavlidis, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
Thoracic Cancer.2019; 10(12): 2274.     CrossRef
Erastin/sorafenib induces cisplatin‑resistant non‑small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway
Yu Li, Hengyi Yan, Xiaoman Xu, Hongbo Liu, Cen Wu, Li Zhao
Oncology Letters.2019;[Epub]     CrossRef
Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1
Yan Yang, Caiyu Jiang, Yang Yang, Lu Guo, Jiang Huang, Xingren Liu, Chi Wu, Jun Zou
Biochemical and Biophysical Research Communications.2018; 497(4): 1003.     CrossRef
Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices
Claudio Martín, Andrés F. Cardona, Zyanya Lucia Zatarain-Barrón, Alejandro Ruiz-Patiño, Omar Castillo, George Oblitas, Luis Corrales, Lorena Lupinacci, María Angelina Pérez, Leonardo Rojas, Lisde González, Luis Chirinos, Carlos Ortíz, Mauricio Lema, Carlo
Oncology.2018; 94(5): 297.     CrossRef
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Stella Baliou, Maria Adamaki, Anthony Kyriakopoulos, Demetrios Spandidos, Michalis Panagiotidis, Ioannis Christodoulou, Vassilis Zoumpourlis
International Journal of Oncology.2018;[Epub]     CrossRef